Full history for every metric is available with a Kvantra account
Invitae Corporation (NVTA)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 68 | 148 | 217 | 280 | 460 | 516 | 482 |
| Operating profit | $m | -714 | -1,461 | |||||
| Net profit | $m | -123 | -129 | -242 | -609 | -379 | -3,106 | -1,441 |
| EPS reported | $ | -13.18 | -5.38 | |||||
| Operating cashflow per share | $ | -2.09 | -2.09 | |||||
| Capex per share | $ | 0.23 | 0.23 | |||||
| FCF per share | $ | -2.32 | -2.32 | |||||
| Free cash flow | $m | -546 | -248 | |||||
| Net debt | $m | 1,204 | 1,096 | |||||
| Book value equity | $m | 102 | - | |||||
| Book value per share | $ | 0.43 | - | |||||
| Number of shares | m | 235.68 | 275.6 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.04 | 0.04 | |||||
| P/S LTM | x | 0.01 | 0.01 | |||||
| P/FCF LTM | x | -0.01 | -0.02 | |||||
| EV/EBITDA LTM | x | -0.52 | -0.89 | |||||
| EV/Sales LTM | x | 2.90 | 2.29 | |||||
| Earnings Yield LTM | % | -70862.1% | -69370.3% | |||||
| FCF Yield | % | -12461.8% | -4552.7% | |||||
| Quality | ||||||||
| ROE | % | -3050.3% | -201.69% | |||||
| ROIC | % | -37.74% | -37.74% | |||||
| Operating margin | % | -138.34% | -138.34% | |||||
| Gross margin | % | 19.18% | 19.18% | |||||
| FCF/Sales | % | -105.80% | -105.80% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +12.13% | -7.38% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.31 | -0.16 | |||||
| Net Debt/EBITDA | x | -0.52 | -0.52 | |||||
| EBIT/Net interest | x | -12.59 | -12.59 | |||||
| Net debt/market cap | % | 27464.0% | 20142.1% | |||||
| Net debt/Equity | x | 11.82 | - | |||||
| Gross debt/equity | x | 17.19 | - | |||||
Company overview
Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Invitae Corporation (NVTA)
Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free